Work

EV-103 study: A phase 1b dose-escalation and dose-expansion study of enfortumab vedotin in combination with immune checkpoint inhibitor (CPI) therapy for treatment of patients with locally advanced or metastatic urothelial cancer.

Year: 2018

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2018.36.6_suppl.tps532

Authors: Christopher J. Hoimes, Daniel Peter Petrylak, Thomas W. Flaig, Anne-Sophie Carret, Amal Melhem-Bertrandt, Jonathan E. Rosenberg

Institutions: University Hospitals Cleveland Medical Center, Case Western Reserve University, Yale University, University of Colorado Cancer Center, Seagen (United States), Astellas Pharma (United States), Memorial Sloan Kettering Cancer Center

Language: English

Topic: Bladder and Urothelial Cancer Treatments

Subfield: Surgery

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2791554036

Cites:

Cited by: 6

Related to: 10